surmount-osa trial tirzepatide results for the Treatment of Obstructive Sleep Apnea and Obesity 🔗 @NEJM 🔗 https://t.co/RKdvTJxd7Y #ADA2024 SURPASS to SURMOUNT: The Tirzepatide

At launch, the pill isn't available on the NHS

The antioxidant properties of Glutathione help to strengthen the body's natural defenses

In a large Phase 3 clinical trial published in the New England Journal of Medicine, people who took the highest dose of the Wegovy pill lost an average of 16.6 percent of their body weight after 64 weeks

These changes happen before your scale shows significant movement, which is why tracking non-scale victories matters during early weeks

The global Semaglutide market presents a significant opportunity through the development of innovative oral formulations and alternative delivery methods, expanding accessibility and patient compliance

Even at the common maintenance dose of 0.5mg per week, you still get 10 weeks